| scholarly article | Q13442814 |
| P50 | author | François Ghiringhelli | Q40399221 |
| Bruno Chauffert | Q40457597 | ||
| François Martin | Q41019017 | ||
| Eric Solary | Q41021747 | ||
| P2093 | author name string | Carmen Garrido | |
| François Ghiringhelli | |||
| Bruno Chauffert | |||
| Bernard Bonnotte | |||
| Nicolas Larmonier | |||
| Arnaud Parcellier | |||
| Elise Schmitt | |||
| Dominique Cathelin | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 336-344 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | European Journal of Immunology | Q5412727 |
| P1476 | title | CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative | |
| P478 | volume | 34 |
| Q61805238 | A Porcine Wound Model of Infection |
| Q35512402 | A distinct chemokine axis does not account for enrichment of Foxp3(+) CD4(+) T cells in carcinogen-induced fibrosarcomas. |
| Q36616446 | A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice |
| Q92247819 | A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer |
| Q33579629 | A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma |
| Q36444022 | A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver |
| Q41002117 | A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer |
| Q33829731 | A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice |
| Q36403371 | A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice |
| Q34330865 | A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. |
| Q42690847 | A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice |
| Q36744405 | Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuv |
| Q48238878 | Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. |
| Q38764852 | Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. |
| Q26795540 | Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors |
| Q38171325 | Adoptive immunotherapy of metastatic breast cancer: present and future |
| Q36974722 | Advances in dendritic-cell-based therapeutic vaccines for cervical cancer |
| Q34138598 | Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide |
| Q34667551 | Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. |
| Q41128106 | Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma. |
| Q27024830 | An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma |
| Q84459533 | Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms |
| Q104459021 | Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells |
| Q34668901 | Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma |
| Q36482356 | Antitumor effect of a polypeptide fraction from Arca subcrenata in vitro and in vivo |
| Q89910802 | Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis |
| Q37270469 | Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression |
| Q36193004 | Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q35901282 | Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. |
| Q51591010 | Associations of Selected Cytokines Levels in Organ Transplant Recipients Without and With Malignant Skin Neoplasms. |
| Q48834589 | Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D. |
| Q38034270 | Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity |
| Q90811874 | Autres immunothérapies |
| Q84633735 | B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets |
| Q37700356 | Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies |
| Q37590606 | Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer. |
| Q37732959 | Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. |
| Q37899223 | Bugs and drugs: oncolytic virotherapy in combination with chemotherapy |
| Q64379277 | Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L |
| Q97067646 | CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape |
| Q37228055 | CD 4+ T cells in the pathobiology of neurodegenerative disorders |
| Q34427580 | CD4 T cells in tumor immunity |
| Q36498454 | CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity |
| Q48185876 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth |
| Q36915014 | CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer |
| Q36403637 | CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner |
| Q64898964 | Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors? |
| Q26863779 | Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances |
| Q35033249 | Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. |
| Q27024438 | Cancer vaccines |
| Q45869011 | Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model. |
| Q37283379 | Cellular immunotherapy for ovarian cancer |
| Q33851844 | Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis |
| Q38611369 | Checkpoint blockade in combination with cancer vaccines |
| Q34058792 | Chemoimmunotherapy |
| Q38079749 | Chemoimmunotherapy: reengineering tumor immunity |
| Q53870991 | Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. |
| Q28384980 | Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism |
| Q38207980 | Chemotherapeutic targeting of cancer-induced immunosuppressive cells |
| Q38223419 | Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer |
| Q34909777 | Chemotherapy and tumor immunity: an unexpected collaboration |
| Q40123387 | Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus |
| Q46018300 | Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. |
| Q35269390 | Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation |
| Q37403295 | Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells |
| Q64096560 | Clinical significance of CD8 T cell immunoreceptor with Ig and ITIM domains in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy |
| Q36488894 | Clinical utilization of chemokines to combat cancer: the double-edged sword |
| Q42725940 | Colon cancer and the immune system: the role of tumor invading T cells |
| Q36253709 | Combination approaches to potentiate immune response after photodynamic therapy for cancer |
| Q35203752 | Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q38167887 | Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells |
| Q37772085 | Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience |
| Q39549328 | Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity |
| Q36906616 | Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity |
| Q59356912 | Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors |
| Q37507346 | Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. |
| Q37320494 | Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice |
| Q37015096 | Combined use of cyclophosphamide and Chalone 19-peptide in experimental breast cancer |
| Q37995939 | Combining immunotherapy and targeted therapies in cancer treatment |
| Q49956890 | Commentary: Maintenance of CD8+ T Memory Lymphocytes in the Spleen but Not in the Bone Marrow Is Dependent on Proliferation. |
| Q36960313 | Comparative methodologies of regulatory T cell depletion in a murine melanoma model |
| Q45367630 | Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response |
| Q36399686 | Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells |
| Q50523001 | Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, an |
| Q42288675 | Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models. |
| Q37832967 | Contribution of the immune system to the chemotherapeutic response. |
| Q36600960 | CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model |
| Q53077428 | Critical stoichiometric ratio of CD4(+) CD25(+) FoxP3(+) regulatory T cells and CD4(+) CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia. |
| Q48287471 | Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model |
| Q28076294 | Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment |
| Q64988615 | Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. |
| Q33502208 | Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth |
| Q33896713 | Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs |
| Q42063211 | Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus |
| Q33653210 | Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo |
| Q34732294 | Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. |
| Q54517461 | Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma. |
| Q35012887 | Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination |
| Q39061560 | Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells |
| Q37268005 | Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation |
| Q37102166 | Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody |
| Q92405012 | Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer |
| Q38963228 | Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? |
| Q41247038 | DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer |
| Q39284974 | Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth |
| Q93060366 | Dendritic Cells and Cancer: From Biology to Therapeutic Intervention |
| Q38091116 | Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy |
| Q38795623 | Dendritic cell-derived exosomes for cancer therapy |
| Q24810259 | Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency |
| Q79967042 | Dendritic cells in cancer immunotherapy |
| Q36809776 | Development of TLR9 agonists for cancer therapy |
| Q93098690 | Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity |
| Q64988693 | Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. |
| Q34293038 | Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice |
| Q37494817 | Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. |
| Q34558758 | Dual roles for immune metagenes in breast cancer prognosis and therapy prediction |
| Q39808301 | Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation |
| Q41877240 | Dysfunctional T regulatory cells in multiple myeloma |
| Q38023121 | ENTPD1/CD39 is a promising therapeutic target in oncology |
| Q34619324 | Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers |
| Q40327515 | Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses |
| Q46939007 | Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. |
| Q39848326 | Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma |
| Q37696829 | Effects of combined epidural and general anesthesia on intraoperative hemodynamic responses, postoperative cellular immunity, and prognosis in patients with gallbladder cancer: A randomized controlled trial |
| Q36791766 | Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response |
| Q53394735 | Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. |
| Q27008070 | Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines |
| Q55467906 | Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. |
| Q39250390 | Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma |
| Q33942806 | Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist |
| Q37727283 | Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells |
| Q38525024 | Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression |
| Q37593466 | Enhancing the efficacy of cancer vaccines in urologic oncology: new directions |
| Q35234948 | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. |
| Q82698110 | Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity |
| Q37762274 | Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. |
| Q92628342 | Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model |
| Q37294572 | Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy |
| Q47259728 | Excellent response to chemotherapy post immunotherapy |
| Q37969356 | Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. |
| Q26779184 | Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy |
| Q40847481 | Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators |
| Q29307487 | FOXP3+ regulatory T cells in the human immune system |
| Q59808913 | From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis |
| Q36293995 | From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer |
| Q47852792 | Functional switching and stability of regulatory T cells |
| Q34591128 | GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. |
| Q40067482 | Gammadelta T lymphocytes: a new type of regulatory T cells suppressing murine 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis |
| Q37173478 | Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. |
| Q27021570 | Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy |
| Q37790599 | Harnessing the immune response to treat cancer |
| Q27001449 | Harnessing the intestinal microbiome for optimal therapeutic immunomodulation |
| Q39920459 | High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome |
| Q37199750 | How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development |
| Q37836489 | How to improve the immunogenicity of chemotherapy and radiotherapy |
| Q35078064 | Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response |
| Q37760416 | Human FOXP3 and cancer |
| Q94672638 | Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma |
| Q36849152 | IFN-alpha and novel strategies of combination therapy for cancer |
| Q36965879 | Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors |
| Q41778516 | Immune ambivalence: The schizophrenic bleomycin |
| Q35747826 | Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma |
| Q38729516 | Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. |
| Q34557233 | Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization |
| Q38936705 | Immunogenic Apoptotic Cell Death and Anticancer Immunity |
| Q38548339 | Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy |
| Q42701148 | Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy |
| Q37039588 | Immunological aspects of cancer chemotherapy |
| Q49500054 | Immunological effects of everolimus in patients with metastatic renal cell cancer |
| Q35238258 | Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus |
| Q33613430 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model |
| Q55046017 | Immunological monitoring for prediction of clinical response to antitumor vaccine therapy. |
| Q34187201 | Immunomodulatory effects of cyclophosphamide and implementations for vaccine design |
| Q27027093 | Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy |
| Q35603131 | Immunosuppressive tumor microenvironment in cervical cancer patients |
| Q35719883 | Immunosurveillance and therapy of multiple myeloma are CD226 dependent |
| Q81703535 | Immunotherapy and chemotherapy--a practical partnership |
| Q37061769 | Immunotherapy and immune evasion in prostate cancer |
| Q33848077 | Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation |
| Q36224057 | Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy |
| Q36708792 | Immunotherapy in prostate cancer: emerging strategies against a formidable foe. |
| Q36739767 | Immunotherapy of melanoma: a critical review of current concepts and future strategies |
| Q36881206 | Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy |
| Q42955079 | Impact of 3 Different Short-term Chemotherapy Regimens on Lymphocyte-depletion and Reconstitution in Melanoma Patients |
| Q47346032 | Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. |
| Q24612603 | Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 |
| Q35574242 | In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer |
| Q28732675 | In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration |
| Q39559727 | In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy |
| Q33282703 | Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy |
| Q57220166 | Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes |
| Q34447864 | Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. |
| Q36809762 | Indoleamine 2,3-dioxygenase and tumor-induced tolerance |
| Q38993215 | Induction of Bcl-xL-specific cytotoxic T lymphocytes in mice. |
| Q40167750 | Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine |
| Q45928254 | Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. |
| Q48505173 | Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. |
| Q35051306 | Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state |
| Q34210036 | Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer |
| Q42113273 | Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. |
| Q92635171 | Krebs Cycle Intermediate-Modified Carbonate Apatite Nanoparticles Drastically Reduce Mouse Tumor Burden and Toxicity by Restricting Broad Tissue Distribution of Anticancer Drugs |
| Q90233649 | Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression |
| Q58552961 | Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients |
| Q33993679 | Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors |
| Q89551648 | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway |
| Q37728232 | Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease |
| Q36527473 | Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine |
| Q48633948 | Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. |
| Q33871059 | Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity |
| Q50924443 | Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. |
| Q37374278 | Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. |
| Q53283435 | Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma. |
| Q86990832 | Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes |
| Q48346696 | Maintenance of memory CD8 T cells: Divided over division |
| Q38253084 | Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy |
| Q37756417 | Manipulation of regulatory T-cell function by immunomodulators: a boon or a curse? |
| Q34661793 | Mechanisms of malignant glioma immune resistance and sources of immunosuppression |
| Q42145973 | Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities |
| Q33604925 | Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q47103586 | Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key. |
| Q38006448 | Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package |
| Q39290128 | Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo |
| Q37763502 | Metronomic chemotherapy: new rationale for new directions |
| Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
| Q39474140 | Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome |
| Q39695611 | Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma |
| Q86328955 | Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer |
| Q37942484 | Metronomic therapy concepts in the management of adrenocortical carcinoma |
| Q49923362 | Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma |
| Q42851616 | Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice. |
| Q55007606 | Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. |
| Q36949870 | Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference |
| Q37547268 | Multipeptide vaccination in cancer patients. |
| Q40798040 | Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma |
| Q36332711 | Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells |
| Q56898695 | Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth |
| Q34145877 | Neoadjuvant anti-tumor vaccination prior to surgery enhances survival |
| Q27001081 | Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses |
| Q36167957 | Neutropenia exacerbates infection by Acinetobacter baumannii clinical isolates in a murine wound model |
| Q92824998 | Novel Biomarkers for Personalized Cancer Immunotherapy |
| Q41257562 | Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model |
| Q38014834 | Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions |
| Q34940971 | Novel therapeutic strategies for targeting liver cancer stem cells |
| Q37273138 | OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. |
| Q37171980 | Oncolytic virotherapy as a personalized cancer vaccine |
| Q21245758 | Oncolytic viruses as therapeutic cancer vaccines |
| Q37300008 | Oncolytic viruses: a novel form of immunotherapy |
| Q37294314 | Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. |
| Q34189694 | Overview of cellular immunotherapy for patients with glioblastoma. |
| Q33823499 | Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice |
| Q37442739 | Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. |
| Q45147425 | Peripheral Treg count and it's determinants in unsensitized and sensitized chronic kidney disease patients |
| Q48237896 | Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival |
| Q37693733 | Personalized dendritic cell-based tumor immunotherapy |
| Q37492540 | Pharmacologic and chemical adjuvants in tumor virotherapy |
| Q58562095 | Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma |
| Q36201411 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas |
| Q35834220 | Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer |
| Q33738279 | Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma |
| Q36535358 | Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. |
| Q42683580 | Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen |
| Q56966087 | Phénotypes et fonctions des lymphocytes T en pathologie tumorale |
| Q35925641 | Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase |
| Q36287976 | Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies |
| Q33780751 | Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer |
| Q46920170 | Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study |
| Q39164463 | Preexisting antitumor immunity augments the antitumor effects of chemotherapy |
| Q38058320 | Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape |
| Q36922577 | Profound impairment of adaptive immune responses by alkylating chemotherapy |
| Q37885285 | Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer |
| Q26783675 | Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis |
| Q28248098 | Prospects for exosomes in immunotherapy of cancer |
| Q36254081 | Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer |
| Q30425914 | Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine |
| Q37290704 | Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer |
| Q56980888 | Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia |
| Q36402967 | Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response |
| Q34123238 | Redirecting the immune response: role of adoptive T cell therapy |
| Q33386554 | Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia |
| Q43102151 | Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy |
| Q92129582 | Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? |
| Q26742012 | Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting |
| Q26991447 | Regulatory T cell: a protection for tumour cells |
| Q37027565 | Regulatory T cells and tumour immunity - observations in mice and men. |
| Q38112114 | Regulatory T cells in allogeneic stem cell transplantation |
| Q39044365 | Regulatory T cells in cancer immunotherapy |
| Q38020963 | Regulatory T cells in the central nervous system |
| Q39418860 | Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. |
| Q36430144 | Regulatory T cells, tumour immunity and immunotherapy |
| Q36911411 | Regulatory T cells--the renaissance of the suppressor T cells. |
| Q38023842 | Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective |
| Q26795598 | Relevance of tumor-infiltrating lymphocytes in breast cancer |
| Q38926803 | Renal cancer treatment with recipient lymphocyte infusion enhanced the antitumor effect of nonmyeloablative allogeneic stem cell transplantation |
| Q94340437 | Reply: Forkhead box P3-positive regulatory T cells in immune surveillance and cancer |
| Q41132577 | Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. |
| Q36609898 | Review article: immune suppression and colorectal cancer |
| Q41991396 | Role of Interferon Regulatory Factor 1 in Governing Treg Depletion, Th1 Polarization, Inflammasome Activation and Antitumor Efficacy of Cyclophosphamide. |
| Q37864686 | Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy |
| Q37965750 | Role of myeloid-derived suppressor cells in tumor immunotherapy |
| Q57461797 | Sensitivity of CD3/CD28-stimulated versus non-stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in the differential radiation response |
| Q36432030 | Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. |
| Q48328578 | Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer |
| Q27335748 | Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment |
| Q55362771 | Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. |
| Q37043725 | Special regulatory T-cell review: A rose by any other name: from suppressor T cells to Tregs, approbation to unbridled enthusiasm |
| Q34697795 | Stimulation of anti-tumor immunity by photodynamic therapy |
| Q38065786 | Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. |
| Q37017023 | Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy. |
| Q27026151 | Suppression, subversion and escape: the role of regulatory T cells in cancer progression |
| Q84979126 | Surgically Unresectable Regional Melanoma Metastases in a Patient With Renal Failure and Peripheral Vascular Disease: Are There Safe and Potentially Effective Treatments? |
| Q37514733 | Synergistic antitumor efficacy of antibacterial helvolic acid from Cordyceps taii and cyclophosphamide in a tumor mouse model. |
| Q36476394 | Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer |
| Q49822317 | T cell modulation by cyclophosphamide for tumour therapy. |
| Q37800935 | T regulatory cells in cancer: recent advances and therapeutic potential |
| Q35459820 | T regulatory cells: aid or hindrance in the clearance of disease? |
| Q92534116 | T-Regulatory Cells In Tumor Progression And Therapy |
| Q37454346 | T-regulatory cell modulation: the future of cancer immunotherapy? |
| Q38006901 | T-regulatory cells: key players in tumor immune escape and angiogenesis |
| Q37671730 | Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. |
| Q56888810 | Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative |
| Q27009348 | Targeting and utilizing primary tumors as live vaccines: changing strategies |
| Q37259608 | Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine |
| Q38970585 | Targeting the Bone Marrow Microenvironment. |
| Q38289041 | Targeting the bone marrow microenvironment in multiple myeloma. |
| Q38805897 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy |
| Q35814814 | Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism |
| Q36975757 | The 'kiss of death' by dendritic cells to cancer cells |
| Q49322680 | The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. |
| Q59210075 | The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis |
| Q36677608 | The anticancer immune response: indispensable for therapeutic success? |
| Q37959968 | The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance |
| Q64273734 | The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial |
| Q95936578 | The future of cancer immunotherapy: microenvironment-targeting combinations |
| Q36249962 | The immunotherapy of prostate and bladder cancer. |
| Q38995979 | The importance of correctly timing cancer immunotherapy |
| Q35841503 | The influence of gut microbiota on drug metabolism and toxicity. |
| Q31144277 | The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide |
| Q38059581 | The mechanism of the anticancer function of M1 macrophages and their use in the clinic |
| Q36161201 | The potential of exosomes in immunotherapy |
| Q33631986 | The role of regulatory T cells in cancer |
| Q36652214 | The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression |
| Q31105891 | The safety profile of cyclophosphamide in multiple sclerosis therapy |
| Q35871559 | The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. |
| Q36593753 | The tumor-draining lymph node as an immune-privileged site |
| Q39935569 | Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. |
| Q37474385 | Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation |
| Q91639441 | Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma |
| Q35207161 | Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas |
| Q36350565 | Towards a therapeutic breast cancer vaccine: the next steps |
| Q34795354 | Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes |
| Q35849686 | Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype |
| Q91642619 | Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports |
| Q37419728 | Treatment of lymphoma with adoptively transferred T cells. |
| Q51799863 | Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. |
| Q39937711 | Treg suppress CTL responses upon immunization with HSP gp96. |
| Q56892924 | Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy |
| Q34210664 | Tumor antigen cross-presentation and the dendritic cell: where it all begins? |
| Q36403539 | Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation |
| Q27007772 | Tumor microenvironment: regulatory cells and immunosuppressive cytokines |
| Q36997144 | Tumor stress, cell death and the ensuing immune response. |
| Q35889643 | Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. |
| Q35986612 | Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning |
| Q33943553 | Tumour-infiltrating T-cell subpopulations in glioblastomas |
| Q64108546 | Turning the Tide Against Regulatory T Cells |
| Q34170003 | Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis |
| Q28076497 | Update on immune checkpoint inhibitors in gynecological cancers |
| Q54710399 | VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. |
| Q36490759 | Vaccination for treatment and prevention of cancer in animal models. |
| Q39043404 | Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update |
| Q36907746 | Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice |
| Q38439138 | Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer |
| Q34025664 | mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia |
Search more.